ISSN: 2349-5448

International Journal of Pharmacology and Clinical Research (IJPCR)

IJPCR |Vol.7 | Issue 4 | Oct - Dec -2023

www.ijpcr.com

DOI : https://doi.org/10.61096/ijpcr.v7.iss4.2023.325-331

Review

Current Regulations In Regulatory Afairs

Keshamoni Raju*, D. Venkata Ramana, P. Sai Mounika

Department Of Regulatory Affairs, Holy Mary Institute Of Technology And Science (College Of Pharmacy), Keesara - Bogaram - Ghatkesar Rd, Kondapur, Telangana 501301

*Author for Correspondence: Keshamoni Raju
Email: keshamoniraju7@gmail.com

Published on: 05 Nov 2023

Published by:
DrSriram Publications

Abstract

Drug Regulatory Affairs refers to all aspects within the pharmaceutical development process and how they are subject to various degrees of regulation. Regulatory Affairs (RA), also called Government Affairs, is a profession within regulated industries, such as pharmaceuticals, medical devices, energy, and banking Pharmaceutical regulatory affairs, as a profession and as a profession, have an important role to play in influencing over-the-counter medication politics, medication use and outcomes as well as other aspects of medical care. In many cases, this will be done at the community level with other health care professionals. The following are the various actions that can be applied to drug users. If done, in whole or in part, it will add to the value of drug therapies, making them a safe and affordable use of medications, leading to beneficial results. already exist. This detail is essentially a personalized drug treatment. Identify, assess and evaluate: medication-related problems, symptoms described by patients, self-diagnosed conditions. The pharmacologist and the affected person take on a series of alliances, including the need to take appropriate individual patients, take them together, and explain the need for complementary care. Symptoms are described by patients and self-diagnosed conditions. The pharmacologist and the affected person take on a series of alliances, including the need to take appropriate individual patients, take them together, and explain the need for complementary care. Symptoms are described by patients and self-diagnosed conditions. The elements of the drug itself are taken by appropriate individual patients, taken together, to explain the appropriate complementary care, Diverse Backgrounds from Regulatory Professionals. Most regulatory professionals have a bachelor's degree and more than half have a higher degree, most often in a scientific or technical field. In addition, regulatory professionals have the experience of moving in front of other careers. Although there are regulatory affairs and related fields in university degree and graduate certificate programs, experience is a key asset for regulatory professionals.

Keywords: Regulatory Affairs, manufacturing execution systems (MES). Good Manufacturing Practices (GMP)

INTRODUCTION

Regulatory affairs is a comparatively new profession which developed from the desire of governments to protect public health by controlling the safety and efficacy of products in areas including pharmaceuticals, veterinary medicines, medical devices, pesticides, agrochemicals, cosmetics and complementary medicines.

Regulatory affairs (RA), is a profession within regulated industries. Regulatory affairs also has a very specific meaning within the healthcare industries. The companies responsible for the discovery,′ testing, manufacture and marketing of these products also want to ensure that they supply products that are safe and make a worthwhile contribution to public health and welfare.

Regulatory Affairs Professionals Responsibility

The regulatory professional's job is to keep track of′ the ever-changing legislation in all the regions in which the company wishes to distribute its products. They also advise on the legal and scientific restraints and requirements, and collect, collate and evaluate the scientific data their research and development colleagues are generating.

Regulatory Affairs Professionals Responsibility

They are responsible for the presentation of registration documents to regulatory agencies, and carry out all the subsequent negotiations necessary to obtain and maintain marketing authorization for the products concerned. They give strategic and technical advice at the highest′ level in their companies, right from the beginning of the development of a product, making an important contribution both commercially and scientifically to the success of a development programme and the company as a whole.

Regulatory Affairs Professionals Responsibility
Registration Documents

Healthcare Regulatory Affairs (RA)

The regulatory function in healthcare industries is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals. Regulatory professionals are employed in industry, government′ and academia and are involved with a wide range of products, including:

pharmaceuticals
medical devices
in vitro diagnostics
biologics and biotechnology
nutritional products
cosmetics

Regulatory Landscape and Product development (R&D)

The regulatory strategy and the development plan are evolving documents. They should be reviewed and updated on a regular basis during the product development process.

Step 1: Properly classify your healthcare product′ (i.e., as a drug, a biologic, a medical device or′ a combination product) so that you know which regulatory path to take. If in′ doubt, contact the appropriate regulatory body to confirm the product type and how your product is regulated.

Step 2 ; Identify the claim of your healthcare product so that you know what types of′ studies to conduct to support the claim and your product label. For instance, changing your claim. May change the medical device classification which can lead to different′ regulatory oversight .

Step 3: Determine your healthcare market. This will guide you to the′ requirements that are specific to each jurisdiction. It is important to identify jurisdiction-specific requirements upfront. so that they can be included early in the product development plan.

Step 4: Develop your regulatory strategy by identifying the specific regulatory′ requirements as well as the possible pathway(s) to take. A thorough understanding of these requirements will guide the development of your regulatory strategy.

Step 5: Establish a healthcare product development plan.′ so that the product requirements can be translated into action i.e., who′ does what and by when and for how much. Such plan should be established collaboratively with input from different functional groups. It should include key milestones, critical paths and periodic reviews for "go and no-go" decisions and be updated periodically.

Step 6: Execute the product development plan It is subject-matter experts who′ possess knowledge of the investigational product who must carry out (and be responsible for) the corresponding manufacturing, quality, regulatory, non-clinical and clinical programs, as well as any coordination with third parties.

Step 7: Execute the clinical plan′ . If a clinical program is required in support of the licensing′ application, these studies should be conducted according to good′ clinical practices (GCP) and country-specific requirements, such as ethics approvals and/or necessary regulatory approvals or conducting the clinical trial(s). Often, it helps to have a pre-submission meeting with the regulatory agency prior to submitting a clinical trial application in order to address specific .

Step 8: Collect your data for regulatory submission .Once the data from the′ product design and the manufacturing, quality, non-clinical and clinical programs are available, these data and reports should be collected for inclusion in the regulatory submission.

Step 9: Collate your regulatory submission according to applicable regulatory′ requirements specific to your type of submission. Ensure the completeness of the submission and anticipate the resources needed to address questions from the agency during the submission review. For an innovative healthcare product, it is often recommended to have a pre-submission meeting with your agency prior to submitting the licensing application.

Step 10: Ensure post-marketing compliance.′ Make sure to fulfill all necessary post-marketing obligations.

Quality Management System and Regulatory Compliance Management

A quality management system (QMS) is a collection of business processes focused on achieving quality policy and quality objectives to meet customer requirements. It is expressed as the organizational structure, policies, procedures, processes and resources needed to implement quality management as per regulatory requirement.

Electronic document management

SOP management
Regulatory submission management eCTD management
CAPA management
Change control
Deviation management
Complaints management
Audit management
Learning management and training.

Manufacturing and Regulatory Compliance

Manufacturing compliance comprises the technical, legal and corporate requirements, regulations and practices manufacturers must comply with in order to produce and market products. The risk of non-compliance has become an increasingly major concern in recent years, particularly for manufacturers with operations in multiple countries and jurisdictions. This development has been further heightened by the increasing role of governmental regulatory bodies in industry sectors, along with the emergence of global standards to address the increasingly global nature of manufacturing.

The core mandate guiding FDA regulatory oversight is consumer safety. As a result, the FDA has defined Good Manufacturing Practices (GMP) for both device and drug manufacturers that dictate the necessary measures that must be taken to ensure that quality systems and processes are in place to consistently produce safe, quality products. Therefore, manufacturers in these sectors seek a manufacturing certificate of compliance indicating that they meet GMP. Meeting the challenge of manufacturing regulatory compliance requires establishing a consistent top-down strategy for ensuring compliance across the enterprise. Software developers have responded to this need by creating solutions for managing regulatory compliance within manufacturing execution systems (MES).

For those in manufacturing sectors regulated by the FDA, these′ solutions must be compliant with Title 21 CFR Part 11 and Part 820. Part 11 requires pharmaceutical manufacturers, medical device manufacturers, biotech companies, biologics developers, contact research organizations, and other FDA-regulated industries (with some specific exceptions) to implement controls. These controls include audits, system validations, audit trails, electronic signatures, and documentation for software and systems involved in processing electronic data that are (a) required to be maintained by the FDA predicate rules or (b) used to demonstrate compliance to a predicate rule.

Marketing and advertising

In most product areas where regulatory requirements′ are imposed, restrictions are also placed upon the claims which can be made for the product on labeling or in advertising. The regulatory affairs will take part in the development of the product marketing concepts and is usually required to approve packaging and advertising before it is used commercially.

Regulatory submission processes

Before a new drug or biologic can go to market, a′ submission must be compiled and filed with all relevant regulatory agencies to seek a review and, ultimately, regulatory approval.

1- Review and approval procedures :
a) Pre-submission meeting
b) Pre-submission activities
c) Administrative review
d) Agency review and sponsor response .
e) Activities prior to the agency's decision
f) Decision.

Unlicensed and licensed products

Advertising and promotion
Unlicensed healthcare products:

No advertising or promotion allowed Internationally, regulations exist prohibit the′ advertising or promotion of unlicensed health care products. In Canada, Section 9(1) of the Food and Drugs Act states that "no person shall label, package, treat, process, sell or advertise any drug in a manner that is false, misleading or deceptive or is likely to create an erroneous impression regarding its composition, merit or safety."Since the terms and any proposed indication of unlicensed healthcare products have not been established, advertising such products is not permitted Similar provisions are laid out in the US Code of Federal Regulations (CFR), Title 21, section 312.7(a) and 812.7(a)the promotion of any investigational drug or medical device (including a new use under investigation for an existing device) is expressly prohibited

Advertising and promotion

Why the promotion or advertising of unlicensed′ healthcare products is prohibited ? The primary concern about the promotion or advertising of unlicensed healthcare products or offlabel uses is that a healthcare provider may form an opinion about a product's use on the basis of the claims made by its company before it receives regulatory approval, and that opinion may be incorrect relative to the pending regulatory approval. Such an erroneous opinion on the part of the healthcare provider could lead to incorrect use of the licensed product, thus using the product off-label.

According to the Section 2 of Canada's Food and Drugs Act, an advertisement includes "any representation by any means whatever for the purpose of promoting directly or indirectly the sale or disposal of any food, drug, cosmetic or device. Promotion can take on many forms, including.

Advertisements
Internet sites
Brochures
Exhibition panel
Gifts
Samples
Reprints
Product monographs
A sales representative's activities
Training materials or briefing
Press releases
Meetings or symposia

Different regulatory bodies have different views on advertising healthcare products

Regulatory systems are in place to safeguard the public from false and misleading advertising of healthcare products. However, among jurisdictions, these systems differ on what constitutes advertising and promotional activities, and thus their regulations and enforcement vary as well. To ensure you comply with industry regulations, understand the local requirements. In Canada, advertising is primarily self-regulated and materials are submitted for preclearance on a voluntary basis. Health Canada is ultimately responsible for enforcement (e.g., in cases when advertising may present a significant health hazard such as when a prescription drug is illegally advertised to the general public or an unauthorized health product is promoted.

SOPs to keep advertising in compliance with regulations

Promotional activities should be consistent with the product labelling that has been cleared or approved. Promotional claims should be reliable, accurate, truthful, informative, fair, balanced and up-to-date, and you must be able to substantiate them. The information should not contain misleading or unverifiable statements or omissions likely to induce medically unjustifiable product use or to give rise to undue risks. Any comparison of products should be factual and fair, and you must be′ able to substantiate it.[1,2,3,4,5]

SOPs to keep advertising in compliance with regulations: Promotional activities should be consistent with the product labelling that′ has been cleared or approved. Promotional claims should be reliable, accurate, truthful, informative, fair, balanced and up-to-date, and you must be able to substantiate them. The information should not contain misleading or unverifiable statements or omissions likely to induce medically unjustifiable product use or to give rise to undue risks. Any comparison of products should be factual and fair, and you must be′ able to substantiate it.

CONCLUSION

Finally, ICH looks to the future. It has established a structure to maintain the guidelines, and at the same time is looking to make available information on the ICH process and guidelines to non-ICH regions with the establishment of the Global Cooperation Group. As well as making information available, the group will act as a resource in the understanding, and even acceptance, of many of the guidelines. From an industry perspective globalization is arguably the most important issue it faces, and the ability of these guidelines to effect intra-company globalization is a facet of ICH that cannot be ignored. This is already happening within companies. Its value has not been quantified; however, the companies able to embrace these principles today will be the world leaders tomorrow. Companies who fail to see the value of harmonization—the value that is already being felt by the scientists carrying out the development, and the value that is yet to be realized in the full drug development cycle— will be left at the starting line of the industry's globalization race.

Drug regulation is interplay between law and science, as well as among regulators and pharmaceutical companies, with input and influence from patients and healthcare professionals. These stakeholders help to determine the regulatory environment in each of the seven GCC authorities and cannot be neglected in the course of the assessment of each country's regulatory practices.

A focused view of the regulatory review process and the quality measures currently used to improve the standard of the assessment procedure is critical to underscore the similarities and differences among the GCC regulatory authorities. However, these similarities and differences cannot be exploited unless they are placed in the context of the GCC harmonized strategic plan.

In general, an effective harmonization strategy requires an effective, coordinated approach, legislation and administration at the country and regional level. Regional cooperation is needed to ensure that regulatory capacity is sufficiently developed to meet the demands of the regulatory environment and to ensure that public health protection is the main purpose of a quality review process, which is a critical step to ensure patients' access to safe and effective medicines.

ACKNOWLEDGEMENT

The Authors are thankful to Sura Labs, Dilshukhnagar, Hyderabad for providing the necessary facilities for the research work.

REFERENCES

1. Available from: https://en.wikipedia.org/wiki/International_Council_on_Harmonisation_of_Technical_Requirements_for_Registration_of_Pharmaceuticals_for_Human_Use. Wikipedia.
2. Available from: http://www.ich.org/fileadmin/Public_Web_Site/ABOUT_ICH/Vision/Introduction_to_ICH_24Jun2014.pdf.
3. Available from: http://www.rroij.com/open-access/a-review-on-impact-of-ich-and-its-harmonisation-on-human-health-care-and-pharmaceuticals.pdf.
4. Available from: http://www.ich.org/fileadmin/Public_Web_Site/ABOUT_ICH/Vision/Value_Benefits_for_Regulatory_2010.pdf.
5. Available from: http://apps.who.int/medicinedocs/en/d/Jh2977e/4.html.
6. Available from: http://www.ncbi.nlm.nih.gov/books/NBK174222/.
7. Available from: file:///C:/Users/SURA%20LAB/Downloads/RF_2012_11_Gulf_Region.pdf.
8. Available from: http://www.rroij.com/open-access/a-review-on-impact-of-ich-and-its-harmonisation-on-human-health-care-and-pharmaceuticals.pdf.
9. Available from: http://onlinelibrary.wiley.com/doi/10.1038/clpt.2011.10/abstract.
10. Gupta A, Goel R, Jain S, Vipin Saini A. Review on impact of ICH and its Harmonisation on Human Health Care and Pharmaceuticals. J Pharm Res Clin Pract. 2014;4(2):41-9.
11. Molzon JA, Giaquinto A, Lindstrom L, Tominaga T, Ward M, Doerr P et al.The value and benefits of the International Conference on Harmonisation to drug regulatory authorities: advancing harmonization for better public health. Clin Pharmacol Ther. 2011;89(4):503-12. doi: 10.1038/clpt.2011.10, PMID 21326288.
12. Dixon JR Jr. The International Conference on Harmonization Good Clinical Practice guideline. Qual Assur. The International Conference on Harmonization Good Clinical Practice [guideline]. 1998;6(2):65-74. doi: 10.1080/105294199277860, PMID 10386329.
13. ICH the need to harmonise [online]. [cited May 02 2014]; Available from. Available from: http://www.ich.org/about/history.html.
14. ICH harmonise for better health vision [online]. [cited Apr 25 2014]; Available from. Available from: http://www.ich.org.about/vision.html.
15. ICH steering committee [online]. [cited Apr 25 2014]; Available from. Available from: http://www.ich.org/about/organisation-of-ich/steering.html.
16. ICH global cooperation [online]. [cited Apr 28 2014]; Available from. Available from: http://www.ich.org/about/organisation-of-ich/coopgroup.html.
17. Medical dictionary for regulatory activities management board [online]. [cited May 02 2014]; Available from. Available from: http://www.ich.org/about/organisation-of-ich/meddra.html.
18. Secretariat ICH for better health [online]. [cited Apr 29 2014]; Available from: URL:http:. Available from: http://www.ich.org/about/organisation-of-ich/secretariat.html.
19. Coordinators Organisation of ICH. URL. [cited May 01 2014]; Available from. Available from: http://www.ich.org/about/organisation-of-ich/coordinators.html.
20. Working groups of ICH organisation [online]. [cited Apr 24 2014]; Available from: URL:. Available from: http://www.ich.org/about/organisation-of-ich/working-groups.html.